Digestive Disease Interventions 2020; 04(03): 291-302
DOI: 10.1055/s-0040-1715816
Review Article

The Contemporary Role of Resection and Ablation in Colorectal Cancer Liver Metastases

Mariam F. Eskander
1   Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio
,
1   Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio
,
1   Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio
,
Timothy M. Pawlik
1   Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio
› Institutsangaben

Abstract

Advances in the field of surgical oncology have turned metastatic colorectal cancer of the liver from a lethal disease to a chronic disease and have ushered in a new era of multimodal therapy for this challenging illness. A better understanding of tumor behavior and more effective systemic therapy have led to the increased use of neoadjuvant therapy. Surgical resection remains the gold standard for treatment but without the size, distribution, and margin restrictions of the past. Lesions are considered resectable if they can safely be removed with tumor-free margins and a sufficient liver remnant. Minimally invasive liver resections are a safe alternative to open surgery and may offer some advantages. Techniques such as portal vein embolization, association of liver partition with portal vein ligation for staged hepatectomy, and radioembolization can be used to grow the liver remnant and allow for resection. If resection is not possible, nonresectional ablation therapy, including radiofrequency and microwave ablation, can be performed alone or in conjunction with resection. This article presents the most up-to-date literature on resection and ablation, with a discussion of current controversies and future directions.



Publikationsverlauf

Eingereicht: 17. Mai 2020

Angenommen: 24. Juni 2020

Artikel online veröffentlicht:
10. September 2020

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 
  • References

  • 1 Engstrand J, Nilsson H, Strömberg C, Jonas E, Freedman J. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer 2018; 18 (01) 78
  • 2 Lordan JT, Karanjia ND, Quiney N, Fawcett WJ, Worthington TR. A 10-year study of outcome following hepatic resection for colorectal liver metastases - the effect of evaluation in a multidisciplinary team setting. Eur J Surg Oncol 2009; 35 (03) 302-306
  • 3 Kow AWC. Hepatic metastasis from colorectal cancer. J Gastrointest Oncol 2019; 10 (06) 1274-1298
  • 4 Kelly RJ, Kemeny NE, Leonard GD. Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. Clin Colorectal Cancer 2005; 5 (03) 166-174
  • 5 Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 2015; 102 (10) 1175-1183
  • 6 Morris V, Overman MJ, Jiang ZQ. et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 2014; 13 (03) 164-171
  • 7 Passot G, Chun YS, Kopetz SE. et al. Predictors of safety and efficacy of 2-stage hepatectomy for bilateral colorectal liver metastases. J Am Coll Surg 2016; 223 (01) 99-108
  • 8 Passot G, Chun YS, Kopetz SE. et al. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: impact of RAS mutations. Eur J Surg Oncol 2016; 42 (09) 1378-1384
  • 9 Zimmitti G, Shindoh J, Mise Y. et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 2015; 22 (03) 834-842
  • 10 Kaczirek K, Ciuleanu TE, Vrbanec D. et al. FOLFOX4 plus cetuximab for patients with previously untreated metastatic colorectal cancer according to tumor RAS and BRAF mutation status: updated analysis of the CECOG/CORE 1.2.002 study. Clin Colorectal Cancer 2015; 14 (02) 91-98
  • 11 Yaeger R, Cercek A, Chou JF. et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120 (15) 2316-2324
  • 12 Pietrantonio F, Petrelli F, Coinu A. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51 (05) 587-594
  • 13 Margonis GA, Buettner S, Andreatos N. et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg 2018; 153 (07) e180996
  • 14 Chakedis J, Squires MH, Beal EW. et al. Update on current problems in colorectal liver metastasis. Curr Probl Surg 2017; 54 (11) 554-602
  • 15 Ejaz A, Semenov E, Spolverato G. et al. Synchronous primary colorectal and liver metastasis: impact of operative approach on clinical outcomes and hospital charges. HPB (Oxford) 2014; 16 (12) 1117-1126
  • 16 Silberhumer GR, Paty PB, Denton B. et al. Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. Surgery 2016; 160 (01) 67-73
  • 17 Slupski M, Jasinski M, Pierscinski S, Wicinski M. Long-term results of simultaneous and delayed liver resections of synchronous colorectal cancer liver metastases. ANZ J Surg 2020; 90 (06) 1119-1124
  • 18 Lam VW, Laurence JM, Pang T. et al. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB (Oxford) 2014; 16 (02) 101-108
  • 19 Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006; 93 (07) 872-878
  • 20 Wang ZM, Chen YY, Chen FF, Wang SY, Xiong B. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: a meta-analysis. Eur J Surg Oncol 2015; 41 (09) 1197-1203
  • 21 Mukai T, Uehara K, Goto H. , et al; Nagoya Surgical Oncology Group. Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial). Jpn J Clin Oncol 2017; 47 (07) 597-603
  • 22 Nordlinger B, Sorbye H, Glimelius B. , et al; EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371 (9617): 1007-1016
  • 23 Shindoh J, Loyer EM, Kopetz S. et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012; 30 (36) 4566-4572
  • 24 Heinemann V, von Weikersthal LF, Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15 (10) 1065-1075
  • 25 Loupakis F, Cremolini C, Masi G. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371 (17) 1609-1618
  • 26 Primrose J, Falk S, Finch-Jones M. et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014; 15 (06) 601-611
  • 27 Bridgewater JA, Pugh SA, Maishman T. , et al; New EPOC investigators. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2020; 21 (03) 398-411
  • 28 Loupakis F, Cremolini C, Salvatore L. et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50 (01) 57-63
  • 29 Snyder M, Bottiglieri S, Almhanna K. Impact of primary tumor location on first-line bevacizumab or cetuximab in metastatic colorectal cancer. Rev Recent Clin Trials 2018; 13 (02) 139-149
  • 30 Brouquet A, Overman MJ, Kopetz S. et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 2011; 117 (19) 4484-4492
  • 31 Adam R, Aloia T, Lévi F. et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25 (29) 4593-4602
  • 32 Peeters M, Price TJ, Cervantes A. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28 (31) 4706-4713
  • 33 Viganò L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 2013; 258 (05) 731-740 , discussion 741–742
  • 34 Vauthey JN, Pawlik TM, Ribero D. et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24 (13) 2065-2072
  • 35 Kishi Y, Zorzi D, Contreras CM. et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010; 17 (11) 2870-2876
  • 36 Adam R, de Gramont A, Figueras J. , et al; of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 2015; 41 (09) 729-741
  • 37 Isfordink CJ, Samim M, Braat MNGJA. et al. Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: a systematic review and meta-analysis. Surg Oncol 2017; 26 (03) 257-267
  • 38 Kim D, Cornman-Homonoff J, Madoff DC. Preparing for liver surgery with “Alphabet Soup”: PVE, ALPPS, TAE-PVE, LVD and RL. Hepatobiliary Surg Nutr 2020; 9 (02) 136-151
  • 39 Shindoh J, Tzeng CW, Aloia TA. et al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg 2013; 100 (13) 1777-1783
  • 40 Lam VW, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford) 2013; 15 (07) 483-491
  • 41 Hwang S, Lee SG, Ko GY. et al. Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy. Ann Surg 2009; 249 (04) 608-616
  • 42 Munene G, Parker RD, Larrigan J, Wong J, Sutherland F, Dixon E. Sequential preoperative hepatic vein embolization after portal vein embolization for extended left hepatectomy in colorectal liver metastases. World J Surg Oncol 2013; 11: 134
  • 43 May BJ, Madoff DC. Portal vein embolization: rationale, technique, and current application. Semin Intervent Radiol 2012; 29 (02) 81-89
  • 44 Beal IK, Anthony S, Papadopoulou A. et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol 2006; 79 (942) 473-478
  • 45 Pamecha V, Levene A, Grillo F, Woodward N, Dhillon A, Davidson BR. Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer 2009; 100 (04) 617-622
  • 46 van Lienden KP, van den Esschert JW, de Graaf W. et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol 2013; 36 (01) 25-34
  • 47 Hoekstra LT, van Lienden KP, Doets A, Busch OR, Gouma DJ, van Gulik TM. Tumor progression after preoperative portal vein embolization. Ann Surg 2012; 256 (05) 812-817 , discussion 817–818
  • 48 Moris D, Ronnekleiv-Kelly S, Kostakis ID. et al. operative results and oncologic outcomes of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) versus two-stage hepatectomy (TSH) in patients with unresectable colorectal liver metastases: a systematic review and meta-analysis. World J Surg 2018; 42 (03) 806-815
  • 49 Sandström P, Røsok BI, Sparrelid E. et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a Scandinavian Multicenter randomized controlled trial (LIGRO Trial). Ann Surg 2018; 267 (05) 833-840
  • 50 Schadde E, Raptis DA, Schnitzbauer AA. et al. Prediction of mortality after ALPPS stage-1: an analysis of 320 patients from the International ALPPS Registry. Ann Surg 2015; 262 (05) 780-785 , discussion 785–786
  • 51 Matsuo K, Hiroshima Y, Yamazaki K. et al. Immaturity of bile canalicular-ductule networks in the future liver remnant while associating liver partition and portal vein occlusion for staged hepatectomy (ALPPS). Ann Surg Oncol 2017; 24 (09) 2456-2464
  • 52 Matsuo K, Murakami T, Kawaguchi D. et al. Histologic features after surgery associating liver partition and portal vein ligation for staged hepatectomy versus those after hepatectomy with portal vein embolization. Surgery 2016; 159 (05) 1289-1298
  • 53 Wanis KN, Ardiles V, Alvarez FA. et al. Intermediate-term survival and quality of life outcomes in patients with advanced colorectal liver metastases undergoing associating liver partition and portal vein ligation for staged hepatectomy. Surgery 2018; 163 (04) 691-697
  • 54 Lunardi A, Cervelli R, Volterrani D. et al. Feasibility of percutaneous intrahepatic split by microwave ablation (PISA) after portal vein embolization for hypertrophy of future liver remnant: the radiological stage-1 ALPPS. Cardiovasc Intervent Radiol 2018; 41 (05) 789-798
  • 55 Lewandowski RJ, Donahue L, Chokechanachaisakul A. et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol 2016; 114 (01) 99-105
  • 56 Shah JL, Zendejas-Ruiz IR, Thornton LM. et al. Neoadjuvant transarterial radiation lobectomy for colorectal hepatic metastases: a small cohort analysis on safety, efficacy, and radiopathologic correlation. J Gastrointest Oncol 2017; 8 (03) E43-E51
  • 57 Gabr A, Abouchaleh N, Ali R. et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2018; 29 (11) 1502-1510.e1
  • 58 Teo JY, Allen Jr JC, Ng DC. et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford) 2016; 18 (01) 7-12
  • 59 Garlipp B, de Baere T, Damm R. et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology 2014; 59 (05) 1864-1873
  • 60 Dendy MS, Ludwig JM, Kim HS. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget 2017; 8 (23) 37912-37922
  • 61 van Hazel GA, Heinemann V, Sharma NK. et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34 (15) 1723-1731
  • 62 Moris D, Dimitroulis D, Vernadakis S. et al. Parenchymal-sparing hepatectomy as the new doctrine in the treatment of liver-metastatic colorectal disease: beyond oncological outcomes. Anticancer Res 2017; 37 (01) 9-14
  • 63 Evrard S, Torzilli G, Caballero C, Bonhomme B. Parenchymal sparing surgery brings treatment of colorectal liver metastases into the precision medicine era. Eur J Cancer 2018; 104: 195-200
  • 64 Margonis GA, Sasaki K, Andreatos N. et al. KRAS mutation status dictates optimal surgical margin width in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 2017; 24 (01) 264-271
  • 65 Margonis GA, Sasaki K, Kim Y. et al. Tumor biology rather than surgical technique dictates prognosis in colorectal cancer liver metastases. J Gastrointest Surg 2016; 20 (11) 1821-1829
  • 66 Fretland ÅA, Dagenborg VJ, Bjørnelv GMW. et al. Laparoscopic versus open resection for colorectal liver metastases: the OSLO-COMET randomized controlled trial. Ann Surg 2018; 267 (02) 199-207
  • 67 Fretland ÅA, Kazaryan AM, Bjørnbeth BA. et al. Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial. Trials 2015; 16: 73
  • 68 Guro H, Cho JY, Han HS, Yoon YS, Choi Y, Periyasamy M. Current status of laparoscopic liver resection for hepatocellular carcinoma. Clin Mol Hepatol 2016; 22 (02) 212-218
  • 69 Buell JF, Cherqui D, Geller DA. , et al; World Consensus Conference on Laparoscopic Surgery. The international position on laparoscopic liver surgery: the Louisville Statement, 2008. Ann Surg 2009; 250 (05) 825-830
  • 70 Wakabayashi G, Cherqui D, Geller DA. et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg 2015; 261 (04) 619-629
  • 71 Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection-2,804 patients. Ann Surg 2009; 250 (05) 831-841
  • 72 Vigano L, Laurent A, Tayar C, Tomatis M, Ponti A, Cherqui D. The learning curve in laparoscopic liver resection: improved feasibility and reproducibility. Ann Surg 2009; 250 (05) 772-782
  • 73 Wakabayashi G. What has changed after the Morioka consensus conference 2014 on laparoscopic liver resection?. Hepatobiliary Surg Nutr 2016; 5 (04) 281-289
  • 74 De Andrade JP, Warner SG, Fong Y. Treatment of metastatic colorectal cancer: innovations in surgical techniques. J Surg Oncol 2019; 119 (05) 653-659
  • 75 Nota CL, Woo Y, Raoof M. et al. Robotic versus open minor liver resections of the posterosuperior segments: a multinational, propensity score-matched study. Ann Surg Oncol 2019; 26 (02) 583-590
  • 76 Melstrom LG, Warner SG, Woo Y. et al. Selecting incision-dominant cases for robotic liver resection: towards outpatient hepatectomy with rapid recovery. Hepatobiliary Surg Nutr 2018; 7 (02) 77-84
  • 77 Ocuin LM, Tsung A. Robotic liver resection for malignancy: current status, oncologic outcomes, comparison to laparoscopy, and future applications. J Surg Oncol 2015; 112 (03) 295-301
  • 78 Abdalla EK, Vauthey JN, Ellis LM. et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239 (06) 818-825 , discussion 825–827
  • 79 Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13 (10) 1261-1268
  • 80 NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. 2020 . Available at: https://www.nccn.org/professionals/physician_gls/default.aspx . Accessed May 1, 2020
  • 81 Tanis E, Nordlinger B, Mauer M. et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014; 50 (05) 912-919
  • 82 Ruers T, Punt C, Van Coevorden F. , et al; EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23 (10) 2619-2626
  • 83 Sotirchos VS, Petrovic LM, Gönen M. et al. Colorectal cancer liver metastases: biopsy of the ablation zone and margins can be used to predict oncologic outcome. Radiology 2016; 280 (03) 949-959
  • 84 Wang X, Sofocleous CT, Erinjeri JP. et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 2013; 36 (01) 166-175
  • 85 Venkat SR, Mohan PP, Gandhi RT. Colorectal liver metastasis: overview of treatment paradigm highlighting the role of ablation. AJR Am J Roentgenol 2018; 210 (04) 883-890
  • 86 Machi J, Uchida S, Sumida K. et al. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg 2001; 5 (05) 477-489
  • 87 Gillams A, Goldberg N, Ahmed M. et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol 2015; 25 (12) 3438-3454
  • 88 Wong SL, Mangu PB, Choti MA. et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28 (03) 493-508
  • 89 Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology 2013; 266 (02) 407-430
  • 90 Kron P, Linecker M, Jones RP, Toogood GJ, Clavien PA, Lodge JPA. Ablation or resection for colorectal liver metastases? A systematic review of the literature. Front Oncol 2019; 9: 1052
  • 91 Ruers T, Van Coevorden F, Punt CJ. , et al; European Organisation for Research and Treatment of Cancer (EORTC), Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 2017 109(09):
  • 92 Lubner MG, Brace CL, Hinshaw JL, Lee Jr FT. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S192-S203
  • 93 Shady W, Petre EN, Do KG. et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol 2018; 29 (02) 268-275.e1
  • 94 Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee Jr FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005; 236 (01) 132-139
  • 95 Hickson G, Patel N, King A, Breen D. Morphometric and chronological behavior of 2.45 GHz microwave ablation zones for colorectal cancer metastases and hepatocellular carcinoma in the liver: preliminary report. Abdom Radiol (NY) 2016; 41 (08) 1611-1617
  • 96 Hoffmann R, Rempp H, Erhard L. et al. Comparison of four microwave ablation devices: an experimental study in ex vivo bovine liver. Radiology 2013; 268 (01) 89-97
  • 97 Correa-Gallego C, Fong Y, Gonen M. et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol 2014; 21 (13) 4278-4283
  • 98 Glassberg MB, Ghosh S, Clymer JW. et al. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. OncoTargets Ther 2019; 12: 6407-6438
  • 99 van Tilborg AA, Scheffer HJ, de Jong MC. et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts. Cardiovasc Intervent Radiol 2016; 39 (10) 1438-1446
  • 100 Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology 2009; 251 (03) 933-940
  • 101 Soliman H, Ringash J, Jiang H. et al. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol 2013; 31 (31) 3980-3986
  • 102 Pan CC, Kavanagh BD, Dawson LA. et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010; 76 (3, Suppl): S94-S100
  • 103 Hara W, Soltys SG, Gibbs IC. CyberKnife robotic radiosurgery system for tumor treatment. Expert Rev Anticancer Ther 2007; 7 (11) 1507-1515
  • 104 Mahadevan A, Blanck O, Lanciano R. et al. Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol 2018; 13 (01) 26
  • 105 Scheffer HJ, Melenhorst MC, Echenique AM. et al. Irreversible electroporation for colorectal liver metastases. Tech Vasc Interv Radiol 2015; 18 (03) 159-169
  • 106 Lyu C, Lopez-Ichikawa M, Rubinsky B, Chang TT. Normal and fibrotic liver parenchyma respond differently to irreversible electroporation. HPB (Oxford) 2019; 21 (10) 1344-1353
  • 107 Scheffer HJ, Nielsen K, van Tilborg AA. et al. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study. Eur Radiol 2014; 24 (10) 2467-2475
  • 108 Scheffer HJ, Vroomen LG, Nielsen K. et al. Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial). BMC Cancer 2015; 15: 772
  • 109 Vroomen L, Ruarus A, Scheffer H, van Kuijk C, van den Tol P, Meijerink M. Ablation of colorectal liver metastases by irreversible electroporation: final results of the COLDFIRE-2 Trial. J Vasc Interv Radiol 2018; 29 (04) S168-S169
  • 110 Pompili M, Francica G. Irreversible electroporation for hepatic tumors. J Ultrasound 2019; 22 (01) 1-3
  • 111 Puijk RS, Ruarus AH, Vroomen LGPH. , et al; COLLISION Trial Group. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer 2018; 18 (01) 821
  • 112 Davidson B, Gurusamy K, Corrigan N. et al. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. Health Technol Assess 2020; 24 (21) 1-38
  • 113 Dalerba P, Sahoo D, Paik S. et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med 2016; 374 (03) 211-222
  • 114 Rodriguez JA, Huerta-Yepez S, Law IK. et al. Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/Stat3 signaling. Cell Mol Gastroenterol Hepatol 2015; 1 (06) 610-630
  • 115 Kingham TP, Nguyen HCB, Zheng J. et al. MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. Oncotarget 2017; 8 (12) 18821-18831
  • 116 Kemeny NE, Chou JF, Boucher TM. et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol 2016; 113 (05) 477-484
  • 117 Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) 2509-2520
  • 118 Datta J, Narayan RR, Kemeny NE, D'Angelica MI. Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review. JAMA Surg 2019; 154 (08) 768-776
  • 119 Kemeny NE, Niedzwiecki D, Hollis DR. et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24 (09) 1395-1403
  • 120 Fiorentini G, Cantore M, Rossi S. et al. Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo 2006; 20 (6A): 707-709
  • 121 D'Angelica MI, Correa-Gallego C, Paty PB. et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg 2015; 261 (02) 353-360